Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Chemotherapy-Induced Neutropenia Treatment Market

Chemotherapy-Induced Neutropenia Treatment Market Share

Report ID: GMI9292
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Chemotherapy-Induced Neutropenia Treatment Market Share

The market encompasses a range of therapeutic interventions aimed at preventing and managing neutropenia, a common complication of chemotherapy. The market is characterized by the presence of established pharmaceutical companies offering innovative treatment options and biosimilar alternatives, along with a growing focus on personalized medicine approaches and targeted therapies. With advancements in oncology research, and expanding patient access to care, the CIN treatment market continues to evolve, catering to the diverse needs of patients undergoing chemotherapy worldwide.

Chemotherapy-Induced Neutropenia Treatment Companies

Prominent players operating in the chemotherapy-induced neutropenia treatment industry include:

Amgen Inc.
BeyondSpring Inc.
Biocon Biologics Inc.
Cellerant Therapeutics
Coherus BioSciences, Inc.
Evive Biotech
Kyowa Kirin Co., Ltd.
Novartis AG
Pfizer Inc.
Sanofi
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Chemotherapy-induced neutropenia treatment market size was USD 584.2 million in 2023 and is expected to register 3.7% CAGR from 2024-2032 owing to the ongoing advancements in treatment options, growing use of chemotherapy, and increase in the cancer incidences worldwide.

The granulocyte colony-stimulating factor segment reached USD 328.5 million in 2023 due to its effectiveness in preventing and managing neutropenia, a common side effect of chemotherapy.

North America chemotherapy-induced neutropenia treatment industry recorded USD 212.7 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to high incidence of cancer, with millions of new cases diagnosed each year in the region.

Amgen Inc., Cellerant Therapeutics, Coherus BioSciences, Inc., Evive Biotech, Kyowa Kirin Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, Spectrum Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are some of the major chemotherapy-induced neutropenia treatment companies worldwide.